Screener
Nektar Therapeutics NKTR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payments of offering costs associated with issuance of common stock and pre-funded warrants | (25) | — |
| Net cash provided by financing activities | 529,549 | 7 |
| Effect of foreign exchange rates on cash and cash equivalents | - | (1) |
| Net increase (decrease) in cash and cash equivalents | 134,462 | (5,358) |
| Cash and cash equivalents at beginning of period | 15,116 | 44,252 |
| Cash and cash equivalents at end of period | $149,578 | $38,894 |
| Non-cash financing activities: | ||
| Offering costs associated with issuance of common stock and pre-funded warrants included in accounts payable and accrued expenses | $565 | — |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's net change in cash?
- Nektar Therapeutics (NKTR) reported net change in cash of $134.46M in Q1 2026.
- How has Nektar Therapeutics's net change in cash changed year-over-year?
- Nektar Therapeutics's net change in cash increased by 2609.6% year-over-year, from -$5.36M to $134.46M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Nektar Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude